Global Prostate Cancer Therapeutics Market
Global Prostate Cancer Therapeutics Market was valued at US$ 9.21 Bn in 2017 and is expected to reach US$ 16.21 Bn by 2026, at a CAGR of 7.33 % during a forecast period.
The objective of the report is to present a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, industry-validated market data and projections with a suitable set of assumptions and methodology. The report also helps in understanding prostate cancer therapeutics market dynamics, structure by identifying and analyzing the market segments and project the global market size. Further, report also focuses on competitive analysis of key players by product, price, financial position, product portfolio, growth strategies, and regional presence. The report also provides PEST analysis, PORTER’s analysis, SWOT analysis to address question of shareholders to prioritizing the efforts and investment in near future to emerging segment in prostate cancer therapeutics market.
Innovations within the development of recent drugs and therapies, sizable amount of recent drugs stepping into the market with FDA approval, high growth in hormone-refractory glandular cancer medicine market, and rise in base of aging population are key driving factors for the expansion of this market. Additionally, rise in prevalence of glandular cancer, dynamic fashion habits of populations, increased patient’s attention awareness, and increasing demand for non-invasive therapies are expected to push the market growth in the forecast period. Alongside these driving factors, the marketplace for prostate cancer is facing some challenges like time overwhelming regulative compliance and high price of prostate drugs. However, the marketplace for prostate cancer is probably going to rise in the forecast period because of the large number of current innovations for the treatment of prostate cancer.
Based on Product Type, Hormone therapy, among product type segments in the prostate cancer therapeutics is highly attractive and is likely to stay this way in the forecast period and is expected to remain dominant throughout the forecast timeframe. Hormonal therapy is also called as androgen deprivation therapy (ADT). The hormone therapy helps to reduce the level of androgens that are male hormones which fuel the growth of cancer. Suppressing the hormone level, the drugs help to decrease the growth of cancer of prostate. The immunotherapy drugs for prostate cancer are projected to register the highest CAGR globally.
In terms of end-user, they are segregated as hospital pharmacy, retail pharmacy, and online pharmacy. The hospital pharmacy accounted for the largest share in the global prostate cancer therapeutics market in 2017. The growing number of the patient pool for medical care in hospitals is the leading factor contributing towards the high share of segment in the global market.
Geographically, North America holds major share in the prostate cancer therapeutics market due to high number of prostate cancer patients whereas APAC and South America are likely to be grow moderately in the prostate cancer therapeutics market due to rising awareness about the disease. Europe is expected to grow at significant rates owing to increase in prevalence rates and developed healthcare infrastructure facilities.
The Scope of Global Prostate Cancer Therapeutics Market:
Global Prostate Cancer Therapeutics Market, by Product Type:
• Hormonal Therapy
o Luteinizing Hormone-releasing Hormone (LHRH) Analogs
o Luteinizing Hormone-releasing Hormone (LHRH) Antagonists
• Targeted Therapy
Global Prostate Cancer Therapeutics Market, by End User:
• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
Global Prostate Cancer Therapeutics Market, by Region:
• North America
• Middle East & Africa
• Asia Pacific
• South America
Key Players Operating In Global Prostate Cancer Therapeutics Market:
• Bristol-Myers Squibb Company
• EUSA Pharma,Inc.
• OSI Retail Pharmacy, Inc.
• Paladin Labs Inc.
• Amgen Inc.
• Cell Genesys Inc.
• Spectrum Retail Pharmacy, Inc.
• Indevus Retail Pharmacy Inc.
• Dendreon Corporation
• Genentech Inc.
• Abbott Laboratories
• GlaxoSmithKline Plc
• Pfizer Inc.
• Immunomedics, Inc.
• Progenics Retail Pharmacy, Inc.
• Takeda Pharmaceutical Company Limited
• Sanofi-Aventis SA
• F. Hoffmann-La Roche Ltd.
• Novartis AG
• ALZA Corporation
• AstraZeneca PLC
Maximize Market Research provides B2B and B2C research on 20,000 high growth emerging opportunities & technologies as well as threats to the companies across the Healthcare, Pharmaceuticals, Electronics & Communications, Internet of Things, Food and Beverages, Aerospace and Defense and other manufacturing sectors.
For More Information Visit here https://www.maximizemarketresearch.com/market-report/global-prostate-cancer-therapeutics-market/25682/
Report Published by https://www.maximizemarketresearch.com MAXIMIZE MARKET RESEARCH
Manik Baug, Vadgaon Bk,
Pune, Maharashtra 411051, India.
+91 96071 95908
This release was published on openPR.
Permanent link to this press release:
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Global Prostate Cancer Therapeutics Market here
News-ID: 1572071 • Views: 533
More Releases from Global Prostate Cancer Therapeutics Market
Global Prostate Cancer Therapeutics Market : Demand Overview, Revenue, Price and …
Researchmoz added Most up-to-date research on "Global Prostate Cancer Therapeutics Market Size, Status and Forecast 2025" to its huge collection of research reports. This report studies the global Prostate Cancer Therapeutics market, analyzes and researches the Prostate Cancer Therapeutics development status and forecast in United States, EU, Japan, China, India and Southeast Asia. This report focuses on the top players in global market, like Sanofi Pfizer Amgen Johnson & Johnson AstraZeneca AbbVie Bayer Ipsen Group Endo Pharmaceuticals Dendreon Corporation (Sanpower
More Releases for Pharma
Global Deferasirox Market 2018 - Novartis, Cipla, Sun Pharma, Natco Pharma
Apex Market Reports, recently published a detailed market research study focused on the “Deferasirox Market” across the global, regional and country level. The report provides 360° analysis of “Deferasirox Market” from view of manufacturers, regions, product types and end industries. The research report analyses and provides the historical data along with current performance of the global PP Pipe industry, and estimates the future trend of Deferasirox on the basis of
Big Pharma Outlook 2026
Boston, MA ReportsWorldwide has announced the addition of a new report title Big Pharma Outlook 2026 to its growing collection of premium market research reports. Pharmavitae Analytics casts its eye out to 2026 with challenging trends in healthcare management set to crystallize, Big Pharma will add $29.5bn in revenues out to 2026, generating $351bn in prescription pharmaceuticals at a low single-digit compound annual growth rate (CAGR) of 0.9%. Using in-house sales forecasts,
Erythrocyte Catalase Market 2017 - Sanofi, Palam Pharma, Bioxera, Zafax Pharma
Apex Research, recently published a detailed market research study focused on the "Erythrocyte Catalase Market" across the global, regional and country level. The report provides 360° analysis of "Erythrocyte Catalase Market" from view of manufacturers, regions, product types and end industries. The research report analyses and provides the historical data along with current performance of the global Erythrocyte Catalase industry, and estimates the future trend of Erythrocyte Catalase market on
12th World Pharma Congress
Conference Series proudly announces 12th World Pharma Congress for 2017, during October 16-18, at Budapest, Hungary. Pharmaceutical innovation is an orderly, predictable process. Intensive research coverage is resulting in an abundant knowledge of the mechanisms driving drug discovery and development. Pharmaceutical Formulation Market size was USD $147billion in 2015 and is anticipated to reach around USD 175.1 billion by 2018. In USA, the total number of new drugs approved between
12th World Pharma Congress
Conference Series has taken an initiation to conduct International Pharma Congress worldwide. From several years Conference Series has been conducting Pharma Congress conferences in major continents like Europe, America and Asia Pacific. Previous conferences were held in city like USA, with success. Conference Series proudly announces 12th World Pharma Congress for 2017, during October 16-18, at Budapest, Hungary. Pharmaceutical innovation is an orderly, predictable process. Intensive research coverage is resulting
4th African Pharma Congress
In the light of this theme, the conference series aims to provide a forum for international researchers from various areas of pharmaceutical sciences like chemical processing, industrial practice, analytical methods and pharmacological actions by providing a platform for critical analysis of new agenda, and to share latest cutting-edge research findings and results about all aspects of Pharmacy We are honoured to invite pharmacists, researchers, professors, scientific communities, delegates, students, business